First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis.
Ottaiano A, De Stefano A, Capozzi M, Nappi A, De Divitiis C, Romano C, Silvestro L, Cassata A, Casaretti R, Tafuto S, Caraglia M, Berretta M, Nasti G, Avallone A.
Ottaiano A, et al. Among authors: casaretti r.
Front Pharmacol. 2018 May 3;9:441. doi: 10.3389/fphar.2018.00441. eCollection 2018.
Front Pharmacol. 2018.
PMID: 29773991
Free PMC article.
Review.